SCHEMBL4890178

SCHEMBL4890178

CCC(C)c1cc(C(C)(C)C)c(O)c(S(=O)(=O)Nc2ccc(C#N)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 3/20 0.47
SLC22A12 Q96S37 2/20 0.45
BRD4 O60885 1/20 0.43
KDM1A O60341 1/20 0.40
CYP26A1 O43174 1/20 0.40
IDH1 O75874 1/20 0.39
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
CYP19A1 P11511 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
BRPF1 P55201 2/20 0.36
NR3C1 P04150 2/20 0.36
PGR P06401 2/20 0.36
NR3C2 P08235 2/20 0.36
AR P10275 2/20 0.36
BRD1 O95696 1/20 0.35
BRPF3 Q9ULD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896279 0.85 SLC22A12 (0.52) MCL1SLC22A12ACLY
SCHEMBL4885016 0.82 BRD4 (0.53) MCL1SLC22A12BRD4KDM1AIDH1
SCHEMBL4896085 0.82 SLC22A12 (0.50) MCL1SLC22A12BRD4KDM1AIDH1
SCHEMBL4893186 0.81 SLC22A12 (0.49) MCL1SLC22A12BRD4KDM1AIDH1
SCHEMBL4890245 0.78 MCL1 (0.54) MCL1SLC22A12BRD4KDM1AIDH1
SCHEMBL4890157 0.73 ALDH1A1 (0.43) MAPTLMNACA1CA2MEN1
SCHEMBL4884903 0.73 CYP1A2 (0.38) MAPTLMNACA1CA2MEN1
SCHEMBL144821 0.71 CA2 (0.50) MAPTLMNACA1CA2MEN1
SCHEMBL4892892 0.70 CRHBP (0.48) MCL1IDH1MAPTLMNACYP19A1
SCHEMBL14023341 0.67 SLC22A12 (0.55) SLC22A12ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US claimed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP claimed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS MCL1 4068/4885SLC22A12 1558/4885BRD4 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.